{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}]}],"title":"Best Confirmed HR-No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Best Confirmed HR-Unable to Determine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}]}],"title":"Best Unconfirmed HR-No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Best Unconfirmed HR-Unable to Determine"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"HR was determined by CBC, differential, and platelet count. Unable to determine = Participants without any valid hematologic assessments.","groups":[{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants in stratum 4: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 10, 13, 19, 25, 31, 37; then every 12 weeks upto 24 months; then once/year; EOT (Median duration of therapy in months: Stratum 4=1.14 [Range: 0.03-3.38])","title":"Best Hematologic Response (HR) At Any Time: Stratum 4 (Ph- ALL/AML)","type":"SECONDARY","unitOfMeasure":"participants"}